<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168348">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02146599</url>
  </required_header>
  <id_info>
    <org_study_id>QPRO-101-SIVQ</org_study_id>
    <nct_id>NCT02146599</nct_id>
  </id_info>
  <brief_title>Patient Perception of Visual Quality and Function</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Optics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Optics</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the visual quality and function of pseudophakic
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Use of corrective visual aids (i.e., spectacles, contact lenses) post Intraocular Lens (IOL) surgery</measure>
    <time_frame>Baseline and 1 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients will be assessed at a baseline visit and a visit 1 week later.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Pseudophakic</arm_group_label>
    <description>.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Administration of patient self assessment</intervention_name>
    <arm_group_label>Pseudophakic</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Bilaterally-implanted pseudophakic subjects over 22 years of age who meet the inclusion
        criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Minimum 22 years of age

          -  Pseudophakic patients who have been  bilaterally implanted with the same type of
             intraocular lenses in both eyes

          -  Ability to understand, read and write English to give consent and complete the study
             questionnaires

          -  Availability, willingness, and sufficient cognitive awareness to comply with
             examination procedures and study visits

          -  Signed informed consent and Health Insurance Portability and Accountability Act
             (HIPAA) authorization

          -  Other protocol-defined inclusion criteria might apply

        Exclusion Criteria:

          -  Any ocular pathology of clinical significance, as determined by the investigator,
             that may affect visual outcomes or influence subjective ocular/visual symptoms

          -  Patient is pregnant or is lactating

          -  Concurrent participation or participation within 30 days prior in any other clinical
             trial

          -  Other protocol-defined exclusion criteria might apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anne Buteyn</last_name>
    <phone>920-564-2180</phone>
    <email>anne.buteyn@amo.abbott.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Debbie Trentacost</last_name>
    <phone>714-247-8625</phone>
    <email>debra.trentacost@amo.abbott.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Daniel Chang, M.D.</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacque Whinery</last_name>
      <phone>661-325-3937</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 4, 2014</lastchanged_date>
  <firstreceived_date>May 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
